Cannabinoids, which in the cannabis they function as an immune system helping them to fight different predators, they are biologically active chemists and are mainly responsible for the therapeutic properties of cannabis. To date, more than 100 different cannabinoids have been identified (which when they come from a plant are called phytocannabinoids) present in this plant. However, the most studied and for which there is more evidence of its benefits are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), although the continuous study of the plant is producing data that suggest that other cannabinoids ( and even other components, such as terpenes) may contribute to its therapeutic effects1.

Cannabinoids are biologically active, as they interact with the endocannabinoid system. This system includes receptors to which different cannabinoids can join (similar to what endocanniboids do, which refer to cannabinoids produced by the human body, such as anandamide and 2-arachidonoylglycerol or 2-AG), and it is through activation / inhibition of these receptors that cannabinoids exert their therapeutic benefits.

Delta-9-tetrahydrocannabinol (Δ9-THC, or THC for simplicity): THC is one of the best known and most studied phytocannabinoids. Much of its fame comes from the fact that the psychotropic effects associated with cannabis are derived from its action (it is for this reason the most sought-after cannabinoid for recreational use). However, it is currently receiving much attention from the scientific community since many of the benefits associated with cannabis are the result of the action of THC in the endocannabinoid system. There are several benefits associated with THC, but those for which there is more clinical evidence are: the reduction of nausea and vomiting in adults (especially in cancer patients undergoing chemotherapy), the reduction of pain symptoms in patients who suffer from chronic pain2 (the use of cannabis in the management of pain symptoms has led many patients to start replacing their conventional pain medications - opiates, with cannabinoid based medications, which in many cases are more efficient with fewer side effects of lesser gravity3), reduction of muscle spasms in patients with multiple sclerosis4, improved sleep in patients suffering from sleep disorders (mainly disorders associated with obstructive sleep apnea syndrome, fibromyalgia, chronic pain and multiple sclerosis)2, appetite stimulation in patients undergoing cancer treatments or with HIV2.

Cannabidiol (CBD): CBD, currently, will be the cannabinoid that has received the most attention by the scientific community. Not only does it not induce any psychotropic effect (unlike THC), it also appears to reduce some of the unwanted effects associated with consuming higher doses of THC.5 In addition, it was the World Health Organization (WHO) that stated that “in humans, CBD does not demonstrate any indicative effects of abuse or any potential for addiction (…) To date, there is no evidence of public health problems associated with use of pure CBD ”, meaning that CBD is well tolerated and has a good safety profile when consumed.6 As for its therapeutic benefits, CBD will be the cannabinoid that has been shown to have broader therapeutic applications. CBD has already been shown to have neuroprotective properties7, which result from the anti-inflammatory properties8 and antioxidants9, antidepressant properties10, antipsychotic11analgesics12, anti-tumor13anxiolytics14, anticonvulsant effects15, among others already assigned. However, looking at the scientific evidence, we find that where the CBD has truly proven its effectiveness was in the treatment of some of the most cruel syndromes of childhood epilepsy (such as the Dravet and Lennox-Gastaut syndromes), where it reduced on a large scale the number of seizures that children with these pathologies suffered daily, allowing a substantial improvement in their quality of life.16 The other properties already identified, although they have been scientifically proven, need further studies in more patients for the effectiveness of CBD to be properly established. Even so, this cannabinoid has immense therapeutic potential, which means that it is being used in the most varied areas. In addition to being part of medicines, we found CBD in dermocosmetic products. Here, its use as therapy has had very promising results, due to its anti-inflammatory, antioxidant properties17 and its ability to soften the skin18. We see CBD also being used in food supplements and even in veterinary products, with several reports of success.

In addition to CBD and THC, there are other cannabinoids that have shown a high therapeutic potential and have attracted the attention of the scientific community, even though the study of their properties is in the beginning (at least when compared with THC and CBD).

Cannabichrome (CBC): another major phytocannabinoid found in the cannabis plant that also does not induce any psychotropic effect. It has already been shown to have anti-inflammatory, antibacterial and antifungal properties.19

Cannabigerol (CBG): this cannabinoid, which is found in most cannabis varieties, in addition to having no psychotropic effect, has shown great therapeutic potential. It has already revealed important antibiotic effects and has the potential to reduce intraocular pressure (important in the treatment of glaucoma). In addition, it has been shown to have analgesic and anti-inflammatory properties.20 Recent studies have indicated that CBG also has adrenergic, serotonergic, enzyme-modulating and antidepressant properties. In addition, it may have positive effects in conditions such as cancer, general inflammation, some skin diseases and inflammatory bowel diseases.21

Tetrahydrocannabivarin (Δ9-THCV, or THCV for simplicity): as the name implies, THCV is very similar at the molecular level to THC (although it is only noticeable in most cannabis varieties). This phytocannabinoid, despite containing psychotropic properties, manages to contradict the undesirable side effects normally associated with THC22 (for example, THCV is an appetite suppressant which will contradict the appetite-stimulating effects of THC23). Its therapeutic potential is very large, and it has already been shown to have antioxidant properties that result in neuroprotective properties (it can be a promising therapy in relieving the symptoms of Parkinson's disease and it can also delay the neurodegeneration resulting from that disease, and it can improve the symptoms resulting from schizophrenia. )24. It also has anti-inflammatory properties25, has already been shown to promote bone growth (having enormous potential in the treatment of osteoporosis) and helps to regulate blood sugar levels (also having potential in the treatment of diabetes)23.

Cannabinol (CBN): it was the first cannabinoid to be identified and isolated (circa 1940)26. Being a THC metabolite, it has mild psychotropic properties, but it also has strong therapeutic potential. CBN has already demonstrated sedative, anticonvulsant, anti-inflammatory and antibiotic properties. Also for topical applications it seems to be useful, showing potential in the treatment of psoriasis and burns.27

  1. Woodbridge M. The premier to medical cannabis. An introductory text to the therapeutic use of cannabis. 2019 Oct, Bedrocan International.
  2. Whiting PF, et al. Cannabinoids for medical use: A systematic review and meta-analysis. Journal of the American Medical Association 313 (24): 2456–2473 (2015).
  3. Boehnke KF, et al. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. Journal of Pain 17 (6): 739–744 (2016).
  4. Koppel BS, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 (17): 1556–1563 (2014).
  5. Niesink RJM, et al. Does cannabidiol protect against adverse psychological effect of THC? Frontiers in Psychiatry. Vol. 4, Article 130, Oct. 2013.
  6. WHO Report. Cannabidiol, Pre-Review Report Item 5.2. 39th Meeting of the Expert Committee on Drug Dependence, 6-10 November 2017.
  7. Sanchez A, et al. Neuroprotective agents: cannabinoids. Clin. Immunol. 2012, 142, 57–67.
  8. Hello A, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J. Clin. Investig. 2014, 124, 3713–3724.
  9. Borges R, et al. Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. Molecules 2013, 18, 12663–12674.
  10. Linge R, et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhancements cortical 5-HT / glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology 2016, 103, 16–26.
  11. Bhattacharyya S, et al. Opposite effects of ∆-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35, 764.
  12. Maione S, et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br. J. Pharmacol. 2011, 162, 584–596.
  13. Massi P, et al. Cannabidiol as potential anticancer drug. Br. J. Clin. Pharmacol. 2013, 75, 303–312.
  14. Elms L, et al. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J. Altern. Complementary Med. 2018
  15. Jones NA, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 2010, 332, 569–577.
  16. Silvestro S, et al. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules 2019, 24, 1459.
  17. Palmieri B, et al. A Therapeutic Effect of CBD-Enriched Ointment in Inflammatory Skin Diseases and Cutaneous Scars. Clin Ter. Mar-Apr 2019; 170 (2): e93-e99.
  18. Eagleston LRM, et al. Cannabinoids in Dermatology: A Scoping Review. Dermatol Online J. 2018 Jun 15; 24 (6).
  19. Turner CE, et al. Biological Activity of Cannabichromene, Its Homologs and Isomers. J Clin Pharmacol. Aug-Sep 1981; 21 (S1): 283S-291S.
  20. Hazekamp A, et al. Chapter 3.24. Chemistry of cannabis, Reference Module in Chemistry, Molecular Sciences and Chemical Engineering Comprehensive Natural Products II Chemistry and Biology Volume 3, 2010, Pages 1033-1084.
  21. https://www.kalapa-clinic.com/en/cannabinoids-and-their-therapeutic-effects/
  22. Englund A, et al. The Effect of Five-Day Dosing With THCV on THC-induced Cognitive, Psychological and Physiological Effects in Healthy Male Human Volunteers: A Placebo-Controlled, Double-Blind, Crossover Pilot Trial. J Psychopharmacol. 2016 Feb; 30 (2): 140-51.
  23. https://www.leafly.com/news/cannabis-101/what-is-thcv-and-what-are-the-benefits-of-this-cannabinoid
  24. García C, et al. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease. British Journal of Pharmacology (2011), 163, 1495-1506.
  25. Bolognini D, et al. The plant cannabinoid Δ9-Tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. British Journal of Pharmacology (2010), 160, 677-687.
  26. Thomas BR, et al. Chapter 1 - The Botany of cannabis sativa L. The Analytical Chemistry of cannabis Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations 2016, Pages 1-26.
  27. Russo EB et al. Chapter Three - cannabis Pharmacology: The Usual Suspects and a Few Promising Leads, Advances in Pharmacology Volume 80, 2017, Pages 67-134.
Scroll to Top

Contact us